Podcast Episodes
Back to Search
May 11, 2026 | CSL Flags $5B Vifor Impairment as Shares Hit Nine-Year Low
CSL's $5B write-down from the Vifor Pharma acquisition sends shares to a nine-year low — the largest single-day drop on record. Inhibrx's INBRX-106 p…
2 months, 1 week ago
May 10, 2026 | Vyvgart Wins Broadest gMG Label; Merck Closes $6.7B Terns Deal
FDA approves Vyvgart for all adult gMG serotypes two daysbefore PDUFA — argenx locks in broadest MG label with no FcRn rival in seronegative disease.…
2 months, 1 week ago
May 08, 2026 | Trump Plans to Fire FDA Commissioner Makary; Leqembi SC Delayed to August
FDA leadership in crisis — multiple outlets report Trump will fire Commissioner Makary after 14 turbulent months. Leqembi SC review extended three mo…
2 months, 2 weeks ago
May 07, 2026 | Angelini's $4.1B Catalyst Buyout; Atara Surges 40% on FDA Path Forward; Roche Acquires PathAI
Angelini Pharma pays $4.1B cash for Catalyst Pharmaceuticals — the fourth biotech buyout this month. Atara surges 40%+ on FDA path to resubmit tab-ce…
2 months, 2 weeks ago
May 06, 2026 | Bayer Acquires Perfuse for $2.45B in Ophthalmology; Novo Wegovy Pill Posts $355M Q1
Bayer bets up to $2.45B on glaucoma drug maker PerfuseTherapeutics — its biggest pharma deal in years. Novo's oral Wegovy hits $355M in Q1, the stron…
2 months, 2 weeks ago
May 05, 2026 | Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off
Myqorzo hits both endpoints in ACACIA-HCM, opening amultibillion-dollar HCM market Camzyos can't reach. Plus: Pfizer scraps its last CD47 program fro…
2 months, 2 weeks ago
May 04, 2026 | SCOTUS Restores Mifepristone Mail Access; First PROTAC Drug Wins FDA Approval
Supreme Court grants emergency stay restoring mifepristone access — and the ruling's implications hit every drugmaker's risk model. Plus: Arvinas/Pfi…
2 months, 2 weeks ago
May 03, 2026 | UCB's $2.2B Candid Therapeutics Deal; FDA Moves to Withdraw Tavneos
UCB drops $2B upfront for Candid Therapeutics' autoimmune T-cell engager cizutamig — their second billion-dollar deal in three weeks. FDA proposes wi…
2 months, 2 weeks ago
May 01, 2026 | FDA Approves First PROTAC Drug Veppanu; Pharma M&A Hits $84B in Q1; Truqap Clears ODAC 7-1
FDA clears Veppanu, the first protein degrader to reachmarket — but no commercial partner in sight. Q1 biopharma M&A hits $84B as patent cliff urgenc…
2 months, 2 weeks ago
Apr 28, 2026 | Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal
Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th dea…
2 months, 3 weeks ago